Literature DB >> 560970

Two dopamine receptors: supportive evidence with the rat rotational model.

N C Tye, L Horsman, F C Wright, B T Large, I A Pullar.   

Abstract

Di-isobutyryl apomorphine (5 mg/kg i.p.) and lergotrile (5 mg/kg i.p.) produce long lasting turning behaviour in rats with 6-hydroxydopamine lesions at the level of the substantia nigra. Haloperidol (1.5 and 3.0 mg/kg p.o.) blocks the rotational behaviour due to the apomorphine ester but has no effect on lergotrile turning. Clozapine (10 and 20 mg/kg p.o.) blocks the lergotrile turning but stimulates the rotational behaviour produced by the apomorphine ester. The results support the concept of two anatomically separate dopamine receptors and their relevance to the study of antipsychotic activity is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 560970     DOI: 10.1016/0014-2999(77)90063-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Striatal dopamine uptake asymmetries and rotational behavior in unlesioned rats: revising the model?

Authors:  R M Shapiro; S D Glick; L B Hough
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Differential behavioral and biochemical effects of four dopaminergic agonists.

Authors:  G Gianutsos; K E Moore
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

3.  Antagonism of apomorphine and lergotrile hypothermia [proceedings].

Authors:  N S Doggett; N A Moore
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

4.  Differential enhancement of locomotor activity by dopamine agonists following chronic morphine treatment.

Authors:  N C Tye; L Horsman; F C Wright; I A Pullar
Journal:  Psychopharmacology (Berl)       Date:  1979-05-15       Impact factor: 4.530

5.  Differential effects of haloperidol and clozapine on attention.

Authors:  M Cheal
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.